Screener
BioMarin Pharmaceuticals BMRN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Payments of contingent consideration | — | — |
| Proceeds from borrowings | 3,650,000 | — |
| Payments of debt issuance costs | (65,604) | — |
| Net cash provided by (used in) financing activities | 3,551,547 | (43,382) |
| Effect of exchange rate changes on cash | (1,630) | (4,479) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (437,674) | 270,974 |
| Cash and cash equivalents: | ||
| Beginning of period | $1,311,679 | $942,842 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's financing cash flow?
- BioMarin Pharmaceuticals (BMRN) reported financing cash flow of $2.74B in Q2 2026.
- How has BioMarin Pharmaceuticals's financing cash flow changed year-over-year?
- BioMarin Pharmaceuticals's financing cash flow increased by 59591.2% year-over-year, from -$4.6M to $2.74B.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about BioMarin Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude